The United States is grappling with a surge in COVID-19 cases attributed to the highly contagious ‘HV.1’ variant, accounting for more than 25% of total infections since the end of October, as reported by media.
According to data from the US Centers for Disease Control and Prevention (CDC), the HV.1 variant, also recognized as EG.5 or Eris, dominated an estimated 25.2% of newly diagnosed cases during the two-week period leading up to October 28. In July, HV.1 represented only 0.5% of total COVID-19 cases, but it has since escalated to surpass 12%, emerging as the predominant strain in the US.
Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center, described HV.1 as a ‘grandchild’ of Omicron in an interview with TODAY.com. He emphasized the propensity of the COVID virus family to mutate, noting that HV.1 remains closely related to existing Omicron subvariants.
Common symptoms associated with the HV.1 variant include congestion, runny nose, headache, fatigue, cough, sore throat, and muscle aches or chills, according to Dr. William.
With the approaching winter season, health officials are closely monitoring the HV.1 variant for potential surges. Following HV.1, other prevalent variants in the United States include EG.5 (Fornax), FL.1.5.1, and XBB.1.16 (Arcturus).
Understanding EG.5 Covid Variant:
The World Health Organization (WHO) has classified the EG.5 strain of the Covid-19 virus as a ‘variant of concern.’ Initially reported on February 17, it was later designated as a variant under monitoring (VUM) on July 19. EG.5, a sub-variant of Omicron, is considered a descendant of the XBB lineage of the virus.
WHO urges countries to share information on the growth advantage of the EG.5 variant and provide its sequence information.
The global health body, along with its Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC), assesses the impact of variants on the performance of COVID-19 vaccines to inform decisions about updates on vaccine composition.
Stay informed with chennaiprint.in as health authorities continue to monitor and respond to the evolving landscape of COVID-19 variants.